 XBiotech Inc. is a clinical-stage biopharmaceutical company focused on developing safermore effective therapeutics through human-based monoclonal antibodies. XBiotechs pipeline consists of 4 candidates with 3 in the pre-clinical phase. Starting 1-2Q 2021, XBiotech aims to re-enter the clinic with more than one new anti-IL-1a therapy. 